NKTR · Nektar Therapeutics Common Stock
View on chartInsiders & Stakes
| Deep Track Capital, LP | ▼ Sell | Open Market | 18,344,000 Shares held | 5/10/2024 | View profile |
| Thomsen Jillian B. SVP & Chief Accounting Officer | ▼ Sell | Open Market | 313,497 Shares held | 2/16/2023 | View profile |
| Gil M. Labrucherie Director | ▼ Sell | Open Market | 312,905 Shares held | 5/16/2022 | View profile |
| NORTHCOTT JOHN SVP & Chief Commercial Officer | ▼ Sell | Open Market | 223,210 Shares held | 5/16/2022 | View profile |
| Howard W. Robin President & CEO | ▼ Sell | Open Market | 54,627 Shares held | 8/18/2026 | View profile |
| Myriam Curet Director | ▼ Sell | Open Market | 27,418 Shares held | 9/18/2023 | View profile |
| Karin Eastham Director | ▲ Buy | Grant | 23,233 Shares held | 9/16/2022 | View profile |
| GREER R SCOTT Director | ▲ Buy | Grant | 22,239 Shares held | 9/23/2026 | View profile |
| Mark Andrew Wilson SVP & General Counsel | ▼ Sell | Open Market | 21,585 Shares held | 11/25/2025 | View profile |
| CHESS ROBERT Director | ▲ Buy | Grant | 19,019 Shares held | 9/23/2026 | View profile |
| WHITFIELD ROY A Director | ▲ Buy | Grant | 16,417 Shares held | 9/23/2026 | View profile |
| Jonathan Zalevsky Chief R&D Officer | ▼ Sell | Open Market | 9,570 Shares held | 8/18/2026 | View profile |
| Ajer Jeffrey Robert EVP, Chief Commercial Officer | ▲ Buy | Grant | 4,277 Shares held | 9/23/2026 | View profile |
| Brainard Diana Director | ▲ Buy | Grant | 3,904 Shares held | 9/23/2026 | View profile |
Transaction History
| WHITFIELD ROY A | ▲ Buy | Grant | 2,000 | $0 | 9/23/2026 |
| GREER R SCOTT | ▲ Buy | Grant | 2,000 | $0 | 9/23/2026 |
| CHESS ROBERT | ▲ Buy | Grant | 2,000 | $0 | 9/23/2026 |
| Brainard Diana | ▲ Buy | Grant | 2,000 | $0 | 9/23/2026 |
| Ajer Jeffrey Robert | ▲ Buy | Grant | 2,000 | $0 | 9/23/2026 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 186 | $13K | 8/18/2026 |
| Howard W. Robin | ▼ Sell | Open Market | 418 | $30K | 8/18/2026 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 5,681 | $398K | 6/30/2026 |
| Howard W. Robin | ▼ Sell | Open Market | 5,500 | $334K | 6/17/2026 |
| Howard W. Robin | ▼ Sell | Open Market | 4,500 | $277K | 6/17/2026 |
| Howard W. Robin | ▼ Sell | Open Market | 5,303 | $318K | 6/16/2026 |
| Howard W. Robin | ▼ Sell | Open Market | 4,697 | $285K | 6/16/2026 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 5,538 | $336K | 6/15/2026 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 199 | $13K | 5/19/2026 |
| Howard W. Robin | ▼ Sell | Open Market | 444 | $29K | 5/19/2026 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 180 | $13K | 2/18/2026 |
| Howard W. Robin | ▼ Sell | Open Market | 423 | $31K | 2/18/2026 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 3,867 | $138K | 1/20/2026 |
| Jonathan Zalevsky | ▲ Buy | Grant | 6,250 | $0 | 12/22/2025 |
| Howard W. Robin | ▲ Buy | Grant | 21,667 | $0 | 12/22/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 1,157 | $63K | 11/25/2025 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 630 | $34K | 11/25/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 2,207 | $120K | 11/25/2025 |
| Jonathan Zalevsky | ▲ Buy | Grant | 2,666 | $0 | 11/21/2025 |
| Mark Andrew Wilson | ▲ Buy | Grant | 1,903 | $0 | 11/21/2025 |
| Howard W. Robin | ▲ Buy | Grant | 7,110 | $0 | 11/21/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 2,100 | $95K | 9/9/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 1,200 | $56K | 9/9/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 2,156 | $102K | 9/9/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 1,210 | $58K | 9/9/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 3,304 | $125K | 9/5/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 2,226 | $86K | 9/5/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 1,136 | $45K | 9/5/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 793 | $26K | 9/4/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 432 | $15K | 9/4/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 189 | $7K | 9/4/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 307 | $11K | 9/4/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 1,923 | $62K | 9/4/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 1,496 | $50K | 9/4/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 613 | $21K | 9/4/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 1,134 | $41K | 9/4/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 485 | $15K | 9/2/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 1,500 | $45K | 9/2/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 725 | $19K | 8/19/2025 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 676 | $18K | 8/19/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 1,573 | $42K | 8/19/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 10,712 | $7K | 5/19/2025 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 9,996 | $7K | 5/19/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 23,208 | $16K | 5/19/2025 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 10,300 | $10K | 2/19/2025 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 11,040 | $11K | 2/19/2025 |
| Howard W. Robin | ▼ Sell | Open Market | 23,774 | $24K | 2/19/2025 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 16,560 | $15K | 12/24/2024 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 33,402 | $30K | 12/23/2024 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 51,115 | $48K | 12/19/2024 |
| Howard W. Robin | ▼ Sell | Open Market | 85,035 | $84K | 12/18/2024 |
| Howard W. Robin | ▼ Sell | Open Market | 46,995 | $47K | 12/17/2024 |
| Jonathan Zalevsky | ▲ Buy | Grant | 135,000 | $0 | 12/13/2024 |
| Mark Andrew Wilson | ▲ Buy | Grant | 165,938 | $0 | 12/13/2024 |
| Howard W. Robin | ▲ Buy | Grant | 410,625 | $0 | 12/13/2024 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 7,785 | $8K | 11/19/2024 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 6,407 | $6K | 11/19/2024 |
| Howard W. Robin | ▼ Sell | Open Market | 16,278 | $16K | 11/19/2024 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 6,866 | $9K | 8/19/2024 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 5,651 | $7K | 8/19/2024 |
| Howard W. Robin | ▼ Sell | Open Market | 14,881 | $19K | 8/19/2024 |
| CHESS ROBERT | ▼ Sell | Open Market | 19,500 | $23K | 6/14/2024 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 7,355 | $13K | 5/17/2024 |
| Howard W. Robin | ▼ Sell | Open Market | 16,650 | $29K | 5/17/2024 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 6,260 | $11K | 5/17/2024 |
| Deep Track Capital, LP | ▼ Sell | Open Market | 56,000 | $100K | 5/10/2024 |
| Howard W. Robin | ▼ Sell | Open Market | 20,033 | $14K | 2/20/2024 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 9,014 | $6K | 2/20/2024 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 7,606 | $5K | 2/20/2024 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 7,179 | $4K | 11/17/2023 |
| Howard W. Robin | ▼ Sell | Open Market | 19,877 | $10K | 11/17/2023 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 9,646 | $5K | 11/17/2023 |
| Myriam Curet | ▼ Sell | Open Market | 4,359 | $3K | 9/18/2023 |
| Ajer Jeffrey Robert | ▼ Sell | Open Market | 4,359 | $3K | 9/18/2023 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 9,703 | $8K | 8/16/2023 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 7,221 | $6K | 8/16/2023 |
| Howard W. Robin | ▼ Sell | Open Market | 19,998 | $16K | 8/16/2023 |
| WHITFIELD ROY A | ▼ Sell | Open Market | 30,000 | $17K | 6/14/2023 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 9,791 | $7K | 5/16/2023 |
| Howard W. Robin | ▼ Sell | Open Market | 20,361 | $15K | 5/16/2023 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 7,543 | $5K | 5/16/2023 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 10,484 | $31K | 2/16/2023 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 8,275 | $25K | 2/16/2023 |
| Thomsen Jillian B. | ▼ Sell | Open Market | 10,267 | $31K | 2/16/2023 |
| Howard W. Robin | ▼ Sell | Open Market | 19,635 | $59K | 2/16/2023 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 13,460 | $48K | 11/16/2022 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 8,690 | $31K | 11/16/2022 |
| Thomsen Jillian B. | ▼ Sell | Open Market | 11,095 | $40K | 11/16/2022 |
| Howard W. Robin | ▼ Sell | Open Market | 38,014 | $136K | 11/16/2022 |
| Myriam Curet | ▼ Sell | Open Market | 4,198 | $13K | 9/23/2022 |
| Ajer Jeffrey Robert | ▼ Sell | Open Market | 4,198 | $13K | 9/23/2022 |
| CHESS ROBERT | ▼ Sell | Open Market | 10,200 | $7K | 9/22/2022 |
| CHESS ROBERT | ▼ Sell | Open Market | 5,100 | $16K | 9/22/2022 |
| Ajer Jeffrey Robert | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 |
| Brainard Diana | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 |
| WHITFIELD ROY A | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 |
| GREER R SCOTT | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 |
| Karin Eastham | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 |
| Myriam Curet | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 |
| CHESS ROBERT | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 |
| Karin Eastham | ▼ Sell | Open Market | 21,267 | $77K | 9/13/2022 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 73,716 | $343K | 8/18/2022 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 3,189 | $15K | 8/16/2022 |
| Thomsen Jillian B. | ▼ Sell | Open Market | 2,006 | $10K | 8/16/2022 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 10,560 | $50K | 8/16/2022 |
| Howard W. Robin | ▼ Sell | Open Market | 13,759 | $65K | 8/16/2022 |
| Howard W. Robin | ▲ Buy | Grant | 410,625 | $0 | 8/15/2022 |
| Mark Andrew Wilson | ▲ Buy | Grant | 165,938 | $0 | 8/15/2022 |
| Thomsen Jillian B. | ▲ Buy | Grant | 165,938 | $0 | 8/15/2022 |
| Jonathan Zalevsky | ▲ Buy | Grant | 135,000 | $0 | 8/15/2022 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 21,673 | $86K | 5/16/2022 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 3,136 | $12K | 5/16/2022 |
| Thomsen Jillian B. | ▼ Sell | Open Market | 5,841 | $23K | 5/16/2022 |
| Howard W. Robin | ▼ Sell | Open Market | 36,529 | $144K | 5/16/2022 |
| NORTHCOTT JOHN | ▼ Sell | Open Market | 4,592 | $18K | 5/16/2022 |
| Gil M. Labrucherie | ▼ Sell | Open Market | 17,448 | $69K | 5/16/2022 |
| Jonathan Zalevsky | ▲ Buy | Grant | 23,950 | $0 | 5/15/2022 |
| Thomsen Jillian B. | ▲ Buy | Grant | 10,950 | $0 | 5/15/2022 |
| Howard W. Robin | ▲ Buy | Grant | 68,450 | $0 | 5/15/2022 |
| Gil M. Labrucherie | ▲ Buy | Grant | 28,750 | $0 | 5/15/2022 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 10,912 | $119K | 2/16/2022 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 3,661 | $40K | 2/16/2022 |
| Thomsen Jillian B. | ▼ Sell | Open Market | 2,363 | $26K | 2/16/2022 |
| Howard W. Robin | ▼ Sell | Open Market | 12,480 | $137K | 2/16/2022 |
| NORTHCOTT JOHN | ▼ Sell | Open Market | 4,852 | $53K | 2/16/2022 |
| Gil M. Labrucherie | ▼ Sell | Open Market | 7,579 | $83K | 2/16/2022 |
| Jonathan Zalevsky | ▲ Buy | Grant | 52,950 | $0 | 12/16/2021 |
| Mark Andrew Wilson | ▲ Buy | Grant | 37,800 | $0 | 12/16/2021 |
| Thomsen Jillian B. | ▲ Buy | Grant | 21,200 | $0 | 12/16/2021 |
| Howard W. Robin | ▲ Buy | Grant | 126,050 | $0 | 12/16/2021 |
| NORTHCOTT JOHN | ▲ Buy | Grant | 37,800 | $0 | 12/16/2021 |
| Gil M. Labrucherie | ▲ Buy | Grant | 52,950 | $0 | 12/16/2021 |
| Gil M. Labrucherie | ▼ Sell | Open Market | 3,000 | $38K | 11/18/2021 |
| Howard W. Robin | ▼ Sell | Open Market | 42,773 | $563K | 11/16/2021 |
| NORTHCOTT JOHN | ▼ Sell | Open Market | 6,061 | $80K | 11/16/2021 |
| Gil M. Labrucherie | ▼ Sell | Open Market | 21,149 | $278K | 11/16/2021 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 20,869 | $275K | 11/16/2021 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 6,564 | $86K | 11/16/2021 |
| Thomsen Jillian B. | ▼ Sell | Open Market | 6,741 | $89K | 11/16/2021 |
| Howard W. Robin | ▲ Buy | Grant | 94,100 | $0 | 11/15/2021 |
| Gil M. Labrucherie | ▲ Buy | Grant | 40,150 | $0 | 11/15/2021 |
| Jonathan Zalevsky | ▲ Buy | Grant | 40,150 | $0 | 11/15/2021 |
| Mark Andrew Wilson | ▲ Buy | Grant | 20,100 | $0 | 11/15/2021 |
| Thomsen Jillian B. | ▲ Buy | Grant | 14,900 | $0 | 11/15/2021 |
| Brainard Diana | ▲ Buy | Grant | 18,360 | $0 | 11/11/2021 |
| GREER R SCOTT | ▲ Buy | Option Exercise | 12,500 | $160K | 11/9/2021 |
| CHESS ROBERT | ▼ Sell | Open Market | 4,600 | $83K | 9/22/2021 |
| Myriam Curet | ▼ Sell | Open Market | 3,665 | $65K | 9/22/2021 |
| Karin Eastham | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 |
| Myriam Curet | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 |
| Ajer Jeffrey Robert | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 |
| WHITFIELD ROY A | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 |
| Ajer Jeffrey Robert | ▼ Sell | Open Market | 3,665 | $65K | 9/22/2021 |
| GREER R SCOTT | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 |
| CHESS ROBERT | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 |
| WHITFIELD ROY A | ▲ Buy | Option Exercise | 40,000 | $552K | 9/16/2021 |
| CHESS ROBERT | ▲ Buy | Option Exercise | 10,279 | $142K | 9/9/2021 |
| CHESS ROBERT | ▼ Sell | Open Market | 10,279 | $165K | 9/9/2021 |
| CHESS ROBERT | ▲ Buy | Option Exercise | 8,000 | $110K | 9/8/2021 |
| CHESS ROBERT | ▼ Sell | Open Market | 8,000 | $128K | 9/8/2021 |
| GREER R SCOTT | ▲ Buy | Option Exercise | 45,000 | $572K | 8/31/2021 |
| CHESS ROBERT | ▼ Sell | Gift | 2,100 | $0 | 8/24/2021 |
| CHESS ROBERT | ▼ Sell | Gift | 2,100 | $0 | 8/24/2021 |
| CHESS ROBERT | ▼ Sell | Gift | 2,100 | $0 | 8/24/2021 |
| CHESS ROBERT | ▼ Sell | Gift | 6,300 | $0 | 8/24/2021 |
| Gil M. Labrucherie | ▼ Sell | Open Market | 3,000 | $41K | 8/17/2021 |
| Jonathan Zalevsky | ▼ Sell | Open Market | 7,662 | $106K | 8/16/2021 |
| Mark Andrew Wilson | ▼ Sell | Open Market | 1,910 | $26K | 8/16/2021 |
| Howard W. Robin | ▼ Sell | Open Market | 11,515 | $159K | 8/16/2021 |
| Thomsen Jillian B. | ▼ Sell | Open Market | 13,339 | $184K | 8/16/2021 |
| NORTHCOTT JOHN | ▼ Sell | Open Market | 6,192 | $86K | 8/16/2021 |
| Gil M. Labrucherie | ▼ Sell | Open Market | 7,867 | $109K | 8/16/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
NKTR receives mixed analyst coverage and pipeline focus
Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.
NKTR receives mixed analyst coverage and pipeline focus. Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.